<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dose response to diltiazem for rate control in atrial fibrillation</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dose response to diltiazem for rate control in atrial fibrillation</h1>
<div class="graphic"><div class="figure"><div class="ttl">Dose response to diltiazem for rate control in atrial fibrillation</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">Kaplan-Meier analysis of the percentage of patients maintaining a therapeutic rate control response to each dose level of intravenous diltiazem infusion in patients who initially responded to bolus diltiazem. Maintenance of rate control was greater at doses of 10 to 15 mg/h.</div><div class="graphic_reference">Data from Ellenbogen KA, Dias VC, Cardello FP, et al. Am J Cardiol 1995; 75:45.</div><div id="graphicVersion">Graphic 80630 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
